A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

A Phase I Study Assessing the Safety and Tolerability of Ascending Doses of AZD1390 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Solid Tumor Malignancies

The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer

Study Overview

• Status: Active, not recruiting
• Conditions: Solid Tumor; Metastatic Cancer; Metastatic Solid Tumor; Solid Tumor, Adult; Solid Carcinoma; Metastatic Tumor
• Intervention / Treatment: Drug: AZD1390; Radiation: Stereotactic Body Radiotherapy

• Study Type: Interventional
• Enrollment (Estimated): 54
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New Jersey
    • Middletown, New Jersey, United States, 07748
      • Memorial Sloan Kettering Monmouth (All Protocol Activities)
  • New York
    • Commack, New York, United States, 11725
      • Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
    • Harrison, New York, United States, 10604
      • Memorial Sloan Kettering Westchester (All Protocol Activities)
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  • Washington
    • Seattle, Washington, United States, 98109
      • University of Washington (Data Collection AND Data Analysis)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Willing and able to provide written informed consent
• Aged at least 18 years.
• Karnofsky Performance Score (KPS) of ≥60.
• Histologically confirmed diagnosis of cancer with clear evidence of metastasis on imaging. Confirmation of metastasis by biopsy is preferred but not required.
• Candidates for SBRT delivered as 6Gy x 5 daily fractions to 2 sites of disease. The radiation plan should meet departmental guidelines. Patients can have more than 2 sites of disease. If patient requires RT to other sites of disease this can be done after completion of DLT period.

• Adequate organ system functions, as outlined below:

  • Absolute neutrophil count (ANC) ≥1.0 x 109/L
  • Platelets ≥75 x 109/L
  • Hemoglobin ≥8 g/dL
  • Total bilirubin ≤1.5 times the ULN
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the ULN if no liver involvement or ≤5 times the ULN with liver involvement with metastatic disease.
  • Creatinine <1.5 times ULN concurrent with creatinine clearance >50 mL/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN.
  • Lipase within normal limits (WNL)
  • Creatine kinase (CK) ≤5 times ULN
• Females of childbearing potential must have a negative pregnancy test during screening and must not be breastfeeding or intending to become pregnant during the study. Male patients with female partners of child-bearing potential must be willing to use two forms of acceptable contraception, including one barrier method, during their participation in this study and for 16 weeks following the last dose of the study drug.
• Ability to swallow and retain oral medication.

Exclusion Criteria:

• Prior radiotherapy to the same region within the last 3 months.
• Ongoing treatment for brain metastases. Patients with brain metastases may participate in this trial however, treatment for brain metastases will have to be completed prior to study enrollment. Treatments can begin or resume two weeks after completing protocol therapy.
• History of epilectic disorder.
• For Arm B patients with cancers involving the spinal cord, the length of the spinal cord lesion requiring palliative treatment is greater than 10 cm.
• Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
• Evidence of established ILD on screening CT scan.
• Evidence of severe pulmonary infections, as judged by the investigator, based on clinical findings and investigations.
• Concurrent severe and/or uncontrolled medical condition (e.g., severe COPD).
• Cardiac dysfunction defined as: Myocardial infarction within six months of study entry, NYHA Class II/III/IV heart failure, unstable angina or unstable cardiac arrhythmias.

• Any of the following cardiac criteria:

  • Mean resting corrected QT interval (QTcF) > 470 msec obtained from 3 electrocardiograms (ECGs) (QTc interval will be calculated using Fridericia's formula).
  • Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block.
  • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age. Patients stable on concomitant medications known to prolong the QT interval may be allowed to participate in the study provided that their mean resting corrected QT interval \(QTcF) is < 470 msec at baseline.
• History or presence of myopathy or raised CK >5 x ULN on 2 occasions at screening.
• Anticancer therapy within 7 days of first SBRT. These treatments should also be held for 7 days after last dose of SBRT. Patients who have received an immune checkpoint inhibitor within 28 days of first administration of study therapy will be excluded.
• History of hypersensitivity to AZD1390 and excipients or drugs with a similar chemical structure or class to AZD1390.
• Patients receiving treatment with strong inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of AZD1390.
• Patients who require sensitive substrates of BCRP, OATP1B1, MATE1, MATE2K and P-gp such as prazosin, cimetidine, simvastatin, dofetilide, metformin, dabigatran, digoxin and fexofenadine should be avoided while on study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A, Dose Level 1; Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target [PTV]) may be triggered at the initial dose level).	Drug: AZD1390; Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80; Radiation: Stereotactic Body Radiotherapy; Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.; Other Names: SBRT
Experimental: Arm A, Dose Level 2; Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target [PTV]) may be triggered at the initial dose level).	Drug: AZD1390; Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80; Radiation: Stereotactic Body Radiotherapy; Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.; Other Names: SBRT
Experimental: Arm A, Dose Level 3; Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target [PTV]) may be triggered at the initial dose level).	Drug: AZD1390; Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80; Radiation: Stereotactic Body Radiotherapy; Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.; Other Names: SBRT
Experimental: Arm A, Dose Level 4; Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target [PTV]) may be triggered at the initial dose level).	Drug: AZD1390; Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80; Radiation: Stereotactic Body Radiotherapy; Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.; Other Names: SBRT
Experimental: Arm B, Dose Level 1; Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target	Drug: AZD1390; Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80; Radiation: Stereotactic Body Radiotherapy; Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.; Other Names: SBRT
Experimental: Arm B, Dose Level 2; Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target	Drug: AZD1390; Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80; Radiation: Stereotactic Body Radiotherapy; Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.; Other Names: SBRT
Experimental: Arm B, Dose Level 3; Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target	Drug: AZD1390; Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80; Radiation: Stereotactic Body Radiotherapy; Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.; Other Names: SBRT
Experimental: Arm B, Dose Level 4; Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target	Drug: AZD1390; Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80; Radiation: Stereotactic Body Radiotherapy; Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.; Other Names: SBRT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess participants for toxicities related to study treatment	The primary objective is to assess the safety and tolerability of concurrent AZD1390 with SBRT for patients with solid tumor metastases with solid tumor metastases. Participant toxicities will be assessed using the CTCAE v5.0	1 year

Collaborators and Investigators

• Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: AstraZeneca
• Investigators: Principal Investigator: Daniel Higginson, MD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

Helpful Links

• Memorial Sloan Kettering Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): May 17, 2023
• Primary Completion (Estimated): May 17, 2028
• Study Completion (Estimated): May 17, 2028

Study Registration Dates

• First Submitted: December 28, 2022
• First Submitted That Met QC Criteria: December 28, 2022
• First Posted (Actual): January 10, 2023

Study Record Updates

• Last Update Posted (Actual): May 18, 2026
• Last Update Submitted That Met QC Criteria: May 14, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Memorial Sloan Kettering Cancer Center; Solid Tumor; Metastatic Cancer; Metastatic Solid Tumor; Solid Carcinoma; Metastatic Tumor; 22-042; AZD1390
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Neoplastic Processes; Pathological Conditions, Signs and Symptoms; Neoplasm Metastasis; Investigative Techniques; Therapeutics; Surgical Procedures, Operative; Radiotherapy; Stereotaxic Techniques; Neurosurgical Procedures; Radiosurgery; AZD1390
• Other Study ID Numbers: 22-042

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No